Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of subcutaneous efgartigimod PH20 in adults with primary immune thrombocytopenia has completed and results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• efgartigimod PH20 subcutaneous (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Primary Immune Thrombocytopenia | Phase 3 | Status: COMPLETED | Results posted: 2024-10-31